JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A4092 CUDC-101
1 Citation

Target: Histone Deacetylases (HDACs)|EGFR|ErbB

Summary: Multitargeted HDAC inhibitor

≥21.7 mg/mL
A4093 ITF2357 (Givinostat)
2 Citation

Target: Histone Deacetylases (HDACs)

Summary: HDAC inhibitor

≥23.8 mg/mL
A4106 Scriptaid
1 Citation

Target: Histone Deacetylases (HDACs)

Summary: HDAC inhibitor,novel and cell-permeable

insoluble in H2O; ≥13.1 mg/mL
A4107 Sodium Phenylbutyrate

Target: Histone Deacetylases (HDACs)

Summary: Histone deacetylase inhibitor

≥27.65 mg/mL
A4094 MC1568
3 Citation

Target: Histone Deacetylases (HDACs)

Summary: Class II HDAC inhibitor,potent and selective

insoluble in EtOH; insoluble in H2O; ≥15.7 mg/mL
A4095 Pracinostat (SB939)
2 Citation

Target: Histone Deacetylases (HDACs)

Summary: Pan-HDAC inhibitor

insoluble in H2O; ≥11.4 mg/mL
A4096 Belinostat (PXD101)
2 Citation

Target: Histone Deacetylases (HDACs)

Summary: Hydroxamate-type HDAC inhibitor

insoluble in H2O; ≥15.92 mg/mL
A4097 CUDC-907

Target: Histone Deacetylases (HDACs)|PI3K

Summary: Potent PI3K/HDAC inhibitor

≥25.45 mg/mL
A4098 PCI-24781 (CRA-024781)

Target: Histone Deacetylases (HDACs)

Summary: Pan-HDAC inhibitor

insoluble in H2O; insoluble in EtOH; ≥11.75 mg/mL
A4099 Valproic acid sodium salt (Sodium valproate)

Target: Histone Deacetylases (HDACs)

Summary: HDAC inhibitor

≥8.35 mg/mL